News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Legal

Latest News

i1-322952-1408686496191.jpg
May 1st 2006
Legal: The Kickback Effect
By R. Christopher Cook, Jesse A. Witten

Criminal penalties for violating the Foreign Corrupt Practices Act can be substantial. Businesses found guilty may be fined upwards of $2.5 million for each offense, or twice the amount gained as a result of the violation.

March 1st 2006

Legal: Hey, Good Lookin': Sex Discrimination in Hiring Reps

By James McDonald, Jr.
January 1st 2006

Legal: Shifting Perspective on Off-Label Promotion

By Jack Cinquegrana, Diana K. Lloyd
November 1st 2005

Legal: State Compulsory Licenses

By Tamsen Valoir
September 1st 2005

Legal: Jumping the Pond

By Mark Herrmann, Richard Elks
Advertisement

Advertisement
i1-170705-1408680993719.jpg

Legal Forum: Loss Causation

ByPamela S. Palmer,Jeff G. Hammel
July 1st 2005

Plantiffs did not try to establish a link between the purported misconduct and the decline in share price. Rather, their sole allegation was that they had paid artificially inflated prices for Dura securities.

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Prev
Advertisement
Advertisement

Trending on PharmExec

1

FDA to Take Action Against Mass-Marketing of Illegal Copycat Drugs: Report

2

Everything to Know About TrumpRx in 2026

3

Novo Nordisk Launches First Super Bowl Commercial for Wegovy Pill

4

Pharmaceutical Executive Daily: The Launch of TrumpRx

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us